You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 2, 2025

Details for Patent: 3,937,838


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 3,937,838
Title: Orally active bronchospasmolytic compounds and their preparation
Abstract:Novel compounds are disclosed having useful activity as bronchodilators of improved longevity of action and reduced incidence of side effects. These compounds are described by the formula: ##EQU1## wherein R.sub.1 is a member of the class consisting of tertiary butyl and cyclobutyl, and R.sub.2 is a hydrogen or 2 to 5 carbon atom acyl radical, and pharmaceutically acceptable salts thereof. The activity of these compounds is compared to previously known bronchodilators such as 1-(3', 5'-dihydroxyphenyl)-2-(isopropylamino)-ethanol, having the common name orciprenaline, and 1-(3', 4'-dihydroxyphenyl-2-isoproplyamino-ethanol, having the common name isoprenaline.
Inventor(s): Wetterlin; Kjell Ingvar Leopold (Sandby, SW), Svensson; Leif Ake (Lund, SW)
Assignee: Aktiebolaget Draco (Lund, SW)
Application Number:05/372,497
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;
Patent landscape, scope, and claims:

United States Patent 3,937,838: A Detailed Analysis of Scope and Claims

Introduction

United States Patent 3,937,838, titled "Orally active bronchospasmolytic compounds and their preparation," is a significant patent in the field of pharmaceuticals, particularly for the treatment of reversible obstructive lung conditions such as asthma. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Background and Invention Overview

The patent, granted to an unspecified assignee, describes compounds effective in treating reversible obstructive lung conditions, with a particular focus on asthmatic conditions. These compounds are characterized by their structural formulas and their therapeutic applications[1].

Key Compounds and Their Structure

The patent introduces two main types of compounds:

  • 1-(3',5'-dihydroxyphenyl)-2-alkylaminoethanols
  • 1-(3',5'-diacyloxyphenyl)-2-alkylaminoethanols

These compounds are noted for their bronchospasmolytic activity, long duration of action, and minimal side effects, especially on the cardiovascular system. The structural formulas include specific substitutions such as tertiary butyl or cyclobutyl groups linked directly to the nitrogen atom, which are crucial for their therapeutic efficacy[1].

Therapeutic Applications

The compounds are designed to act as bronchodilators, providing relief from bronchospasm associated with conditions like asthma. They are distinguished by their weak cardioaccelerating effects, which is a significant advantage over other bronchodilators that often cause cardiovascular side effects[1].

Administration and Formulations

These compounds can be administered in various forms, including oral, bronchial, rectal, or parenteral routes. They can also be formulated as salts with physiologically acceptable acids such as hydrochloric, hydrobromic, or succinic acid, enhancing their stability and bioavailability[1].

Claim Structure and Scope

The patent claims are structured to encompass the specific compounds, their preparation methods, and their therapeutic uses. Here are some key aspects of the claims:

Independent Claims

  • The patent includes claims for the specific chemical structures of the compounds.
  • Claims for the methods of preparing these compounds.
  • Claims for the therapeutic use of these compounds in treating reversible obstructive lung conditions.

Dependent Claims

  • These claims further specify the types of substitutions (e.g., tertiary butyl or cyclobutyl groups) and the forms in which the compounds can be administered (e.g., salts with specific acids)[1].

Patent Scope and Breadth

The scope of the patent is defined by the breadth of its claims. Here, the claims are relatively narrow but specific, focusing on the unique structural features and therapeutic applications of the compounds. This specificity helps in avoiding overly broad claims that might be challenged for lack of clarity or validity[3].

Patent Landscape and Prior Art

The patent landscape for bronchospasmolytic compounds is competitive, with numerous patents and applications filed over the years. The prior art in this field includes various compounds and methods for treating asthma and other respiratory conditions. The uniqueness of this patent lies in the specific structural modifications that enhance the duration of action and reduce side effects[1].

Legal and Regulatory Considerations

Patents, including US 3,937,838, are subject to legal and regulatory scrutiny. Claim construction, a critical aspect of patent law, involves interpreting the language of the claims to determine their scope and validity. The Federal Circuit has established that claim construction is a question of law, subject to de novo review on appeal[2].

Impact on Innovation and Litigation

The granting of this patent reflects the ongoing innovation in pharmaceuticals, particularly in the treatment of respiratory diseases. However, the patent system also faces criticisms regarding patent quality and the potential for overly broad claims. The examination process, as shown in other studies, tends to narrow the scope of patent claims, ensuring that only valid and specific inventions are patented[3].

Conclusion

United States Patent 3,937,838 is a significant contribution to the field of respiratory medicine, offering compounds with improved therapeutic profiles for treating asthma and other obstructive lung conditions. The patent's scope is well-defined, focusing on specific structural modifications and therapeutic applications. Understanding the claims, scope, and broader patent landscape is crucial for both innovators and legal practitioners navigating the complex world of pharmaceutical patents.

Key Takeaways

  • Specific Compounds: The patent describes 1-(3',5'-dihydroxyphenyl)-2-alkylaminoethanols and 1-(3',5'-diacyloxyphenyl)-2-alkylaminoethanols with unique structural features.
  • Therapeutic Applications: These compounds are effective bronchodilators with minimal cardiovascular side effects.
  • Administration Forms: The compounds can be administered orally, bronchially, rectally, or parenterally, and formulated as salts with various acids.
  • Claim Structure: The patent includes independent and dependent claims specifying the compounds, their preparation, and therapeutic uses.
  • Patent Scope and Breadth: The claims are specific and narrow, avoiding overly broad assertions.
  • Legal Considerations: Claim construction and validity are subject to legal scrutiny and de novo review.

FAQs

Q: What are the main compounds described in US Patent 3,937,838?

A: The main compounds are 1-(3',5'-dihydroxyphenyl)-2-alkylaminoethanols and 1-(3',5'-diacyloxyphenyl)-2-alkylaminoethanols.

Q: What is the therapeutic application of these compounds?

A: These compounds are used as bronchodilators to treat reversible obstructive lung conditions, particularly asthma.

Q: How can these compounds be administered?

A: They can be administered orally, bronchially, rectally, or parenterally, and can be formulated as salts with various physiologically acceptable acids.

Q: What makes these compounds unique?

A: They have a long duration of action and cause only very weak side effects, especially on the cardiovascular system.

Q: How are the claims structured in this patent?

A: The patent includes independent claims for the compounds and their preparation, and dependent claims that further specify the types of substitutions and administration forms.

Sources

  1. US3937838A - Orally active bronchospasmolytic compounds and their preparation - Google Patents
  2. VASCULAR SOLUTIONS LLC v. MEDTRONIC, INC. - CAFC
  3. Patent Claims and Patent Scope - SSRN

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 3,937,838

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
No data available in table
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 0 to 0 of 0 entries

Foreign Priority and PCT Information for Patent: 3,937,838

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
14182/66Oct 19, 1966

International Family Members for US Patent 3,937,838

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Austria 286964 ⤷  Subscribe
Austria 287678 ⤷  Subscribe
Austria 287679 ⤷  Subscribe
Austria 288356 ⤷  Subscribe
Belgium 704932 ⤷  Subscribe
Switzerland 510625 ⤷  Subscribe
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 6 of 6 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.